Treating stroke with tissue plasminogen activator (tPA) can help dissolve blood clots and improve outcome. But tPA also increases the risk of hemorrhage and has other deleterious effects. A new approach to treatment minimizes these negative effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kim Caesar
References
Bambauer, K.Z., Johnston, S.C., Bambauer, D.E. & Zivin, J.A. Arch. Neurol. 63, 661–664 (2006).
Armstead, W.M. et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat. Neurosci. 9, 1150–1155 (2006).
Mitka, M. J. Am. Med. Assoc. 289, 1363–1364 (2003).
Lo, E.H. Nat. Med. 10, 1295–1296 (2004).
Nicole, O. et al. Nat. Med. 7, 59–64 (2001).
Wang, X. et al. Nat. Med. 9, 1313–1317 (2003).
Akkawi, S., Nassar, T., Tarshis, M., Cines, D.B. & Higazi, A.A. LRP and alpha(v)beta(3) mediate tPA-activation of smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 291, H1351–H1359 (2006).
Kilic, E. et al. Stroke 36, 332–336 (2005).
Liu, D. et al. Nat. Med. 10, 1379–1383 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dawson, T., Dawson, V. Taming the clot-buster tPA. Nat Med 12, 993–994 (2006). https://doi.org/10.1038/nm0906-993
Issue Date:
DOI: https://doi.org/10.1038/nm0906-993
